Yixintang Pharmaceutical announces shareholder returns, board changes, and project adjustments

Yixintang Pharmaceutical Group announced a shareholder return plan for 2025-2027, committing to annual cash dividends of no less than 20% of distributable profits, with provisions for higher payouts based on company development. The company also announced the completion of its seventh board of directors' election, with Ruan Hongxian re-elected as chairman and general manager. New appointments include Zhang Yong as executive vice general manager, Ruan Aixiang, Ruan Guowei, and Li Zhenghong as vice general managers. Xiao Donglei was appointed chief financial officer, and Li Zhenghong also serves as board secretary.

Additionally, Yixintang will extend the completion date for its "Information Technology Construction Project" and "Chinese Herbal Medicine Production Capacity Expansion Project" to December 2027, citing market changes and evolving business needs. The total investment for these projects remains unchanged at 210,000 yuan and 27,703.54 yuan, respectively, with the "Yixintang (Sichuan) Great Health Smart Medical Base Phase I Logistics Center Project" maintaining its December 2206 completion target with an investment of 10,900 yuan. The company also approved credit applications totaling 726,127 yuan for the group and 14.08 million yuan in guarantees for its subsidiaries, aimed at supporting operational expansion. Routine related-party transactions for 2026, including property leases and product sales/purchases with entities controlled by Ruan Hongxian, Liu Qiong, Red Cloud Pharmaceutical Group, and Yunnan Tonghong Hot Spring, were also approved, reflecting ongoing business needs.